Hence, this is consistent with a bona fide cure of muscular dystrophy in this preclinical model when the next-generation AAV9 vectors that expressed the MD1 and FST genes from the de novo designed SkCRM4-Des promoter. This evidence concerns the gene DES and muscular dystrophy.